These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15531028)

  • 1. Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children.
    Wood C; von Baeyer CL; Bourrillon A; Dejos-Conant V; Clyti N; Abitbol V
    Vaccine; 2004 Nov; 23(2):127-31. PubMed ID: 15531028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of choice of measles-mumps-rubella vaccine on immediate vaccination pain in infants.
    Ipp M; Cohen E; Goldbach M; Macarthur C
    Arch Pediatr Adolesc Med; 2004 Apr; 158(4):323-6. PubMed ID: 15066870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
    Knutsson N; Jansson UB; Alm B
    Vaccine; 2006 Jul; 24(31-32):5800-5. PubMed ID: 16765490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain response to M-M-R vaccination in 4-6 year old children.
    Ipp M; Cohen E; Goldbach M; Macarthur C
    Can J Clin Pharmacol; 2006; 13(3):e296-9. PubMed ID: 17127775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany.
    Schlipköter U; Mühlberger N; von Kries R; Weil J
    Infection; 2002 Dec; 30(6):351-5. PubMed ID: 12478324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.
    Marshall H; Nolan T; Roberton D; Richmond P; Lambert S; Jacquet JM; Schuerman L
    Vaccine; 2006 Aug; 24(35-36):6120-8. PubMed ID: 16822597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multifactorial strategy of pain management is associated with less pain in scheduled vaccination of children. A study realized by family practitioners in 239 children aged 4-12 years old.
    Boivin JM; Poupon-Lemarquis L; Iraqi W; Fay R; Schmitt C; Rossignol P
    Fam Pract; 2008 Dec; 25(6):423-9. PubMed ID: 18836092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical 4% amethocaine gel reduces the pain of subcutaneous measles-mumps-rubella vaccination.
    O'Brien L; Taddio A; Ipp M; Goldbach M; Koren G
    Pediatrics; 2004 Dec; 114(6):e720-4. PubMed ID: 15574604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of Faces Scale in children's self-assessment of pain].
    Vihunen R; Sihvonen M
    Hoitotiede; 1998; 10(3):123-33. PubMed ID: 10437441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
    Black S; Friedland LR; Schuind A; Howe B;
    Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do physicians immunize their own children? Differences among pediatricians and nonpediatricians.
    Posfay-Barbe KM; Heininger U; Aebi C; Desgrandchamps D; Vaudaux B; Siegrist CA
    Pediatrics; 2005 Nov; 116(5):e623-33. PubMed ID: 16263976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vaccinations in early infancy -- results of an epidemiological cross-sectional study in Hamburg].
    Fell G; David C; Reintjes R
    Gesundheitswesen; 2005 Jan; 67(1):27-32. PubMed ID: 15672303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.
    Jacobsen SJ; Ackerson BK; Sy LS; Tran TN; Jones TL; Yao JF; Xie F; Cheetham TC; Saddier P
    Vaccine; 2009 Jul; 27(34):4656-61. PubMed ID: 19520201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.
    Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B
    Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.